)
Edge11 Sep 2026
Texas Pacific Land Corporation: Keeper of the Permian Basin
Land once granted to a failed 19th-century railroad now generates royalties for Texas Pacific Land Corporation across the Permian Basin.
Intensity Therapeutics
Intensity Therapeutics (INTS) investor relations material
Intensity Therapeutics H.C. Wainwright 28th Annual Global Investment Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H.C. Wainwright 28th Annual Global Investment Conference summary11 Sep, 2026
Conference overview
Over 500 companies presented across life sciences, cryptocurrency, technology, media, and telecommunications sectors.
The event featured one-on-one meetings, corporate presentations, and expert panels.
Technology and clinical development
A novel cancer therapy induces immunogenic cell death using a supramolecular complex for intratumoral injection.
The technology is stable for up to four years and leverages a delivery mechanism similar to that used in the Wegovy pill.
Over 200 patients have been treated in two completed clinical trials, with ongoing phase III and phase II studies in metastatic sarcoma and pre-surgical breast cancer.
Clinical trial results and endpoints
Phase III sarcoma trial targets overall survival, with interim analyses at 20%, 40%, and 60% enrollment.
Phase II breast cancer trial aims for pathological complete response, showing a trend toward improved outcomes and reduced adverse events.
Early data indicate a 20% abscopal effect, with uninjected tumors shrinking and median survival extended to 21 months in some cohorts.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Intensity Therapeutics
- Net loss rose, cash reserves held at $9.5M, and resumed trials showed improved TNBC results.INTS
Q2 2026 - All proposals, including director elections and stock plan amendments, were approved by majority vote.INTSAGM 2026
- Net loss narrowed to $2.4M in Q1 2026; clinical progress and funding remain critical.INTSQ1 2026
- Shareholders will vote on director elections, equity plan changes, and auditor ratification at the 2026 virtual meeting.INTSProxy filing
- Virtual meeting to vote on director elections, auditor, and equity plan amendments.INTSProxy filing
- Promising clinical results and strong 2025 capital raise extend cash runway into Q2 2027.INTSQ4 2025
- Shelf registration enables up to $150M in offerings, supporting late-stage oncology trials.INTSRegistration Filing
- Registering 394,500 shares for resale; lead cancer drug advancing to Phase 3.INTSRegistration Filing
- Directors re-elected, stock plan approved, and auditor ratified with no Q&A from shareholders.INTSAGM 2024
Next Intensity Therapeutics earnings date
Q3 202611 Nov, 2026
Intensity Therapeutics
Next Intensity Therapeutics earnings date
Q3 202611 Nov, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage